Aktuellt
SENASTE
Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.3m (SEK 14.8m in Q3), mostly related to the Day One Biopharmaceuticals partner and the VADA project. Sprint Bioscience continues to market and engage in discussions with potential partners for VP34, TREX1 (DISA), NIMA and MASH programs.
LÄS MER
